by Clinical Neuropsychologist Online | Monday, July 29, 2024 | Dementia
Abstract INTRODUCTION Recent clinical trials of amyloid beta (Aβ)-targeting therapies in Alzheimer’s disease (AD) have demonstrated a clinical benefit over 18 months, but their long-term impact on disease trajectory is not yet understood. We propose a framework...
by Clinical Neuropsychologist Online | Monday, July 29, 2024 | Dementia
Abstract INTRODUCTION Unraveling how Alzheimer’s disease (AD) genetic risk is related to neuropathological heterogeneity, and whether this occurs through specific biological pathways, is a key step toward precision medicine. METHODS We computed pathway-specific...
by Clinical Neuropsychologist Online | Monday, July 29, 2024 | Dementia
Abstract INTRODUCTION COVID-19 had devastating impacts worldwide. However, most research examining the impact of dementia on COVID-19 outcomes has been conducted in Europe and Asia and has not examined dementia subtypes. METHODS A retrospective analysis of electronic...
by Clinical Neuropsychologist Online | Monday, July 29, 2024 | Dementia
Abstract INTRODUCTION Altered neurometabolism, detectable via proton magnetic resonance spectroscopic imaging (1H-MRSI), is spatially heterogeneous and underpins cognitive impairments in Alzheimer’s disease (AD). However, the spatial relationships between...
by Clinical Neuropsychologist Online | Monday, July 29, 2024 | Dementia
Abstract INTRODUCTION We investigate the role of osteopontin (OPN) in participants with Pre-symptomatic Alzheimer’s disease (AD), mild cognitive impairment (MCI), and in AD brains. METHODS Cerebrospinal fluid (CSF) OPN, AD, and synaptic biomarker levels were...
